Benzinga · Aug 28, 2026
BioAtla To Be Delisted From Nasdaq Following Listing Council Decision; Trading Suspension Effective August 31, With Shares Expected To Transition To OTC Markets
-SEC Filing
NASDAQ · BCAB
BioAtla, Inc.
Healthcare · Biotechnology
$1.74
Up+$0.42 (+31.44%)
Updated Sep 16, 2026, 11:09 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 46.1M
- P/E ratio
- -0.94
- Dividend yield
- 0.00%
- 52-week range
- $0.15 – $8.20
- Volume
- 1.03M
- Avg. volume
- 1.41M
Price performance
BCAB price history
1M range · 9 trading sessions · Daily adjusted prices
BCAB closed at $1.74 after 9 trading sessions, down 45.44% for the selected period.
- Last close
- $1.74
- Period change
- -45.44%
- Period low
- $1.74
- Period high
- $3.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $1.58 | $2.0999 | $1.51 | $1.735 | 1.03M |
| Aug 27, 2026 | $3.15 | $3.245 | $3.07 | $3.14 | 31.33K |
| Aug 26, 2026 | $3.35 | $3.37 | $3.06 | $3.12 | 21.47K |
| Aug 25, 2026 | $3.28 | $3.47 | $3.09 | $3.26 | 55.31K |
| Aug 24, 2026 | $3.27 | $4.00 | $3.10 | $3.28 | 393.76K |
| Aug 21, 2026 | $3.26 | $3.41 | $3.03 | $3.18 | 88.74K |
| Aug 20, 2026 | $3.24 | $3.35 | $3.14 | $3.18 | 19.04K |
| Aug 19, 2026 | $3.28 | $3.3253 | $3.04 | $3.27 | 47.22K |
| Aug 18, 2026 | $3.01 | $3.25 | $2.98 | $3.18 | 30.26K |
Latest BCAB news
The latest Smart Investors Daily articles mentioning BCAB.
Stock researchCompany · Overview
BCAB research
Overview
Company profile and research snapshot.
Company profile
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.00
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2025 | JMP Securities | Market Perform | — |
| Mar 31, 2025 | Citizens Capital Markets | Market Outperform | — |
| Mar 31, 2025 | HC Wainwright & Co. | Neutral | — |
| Nov 13, 2024 | HC Wainwright & Co. | Neutral | — |
| Sep 16, 2024 | JMP Securities | Market Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
BioAtla Initiates Exploration Of Strategic Initiatives Including Workforce Reduction Of ~70%; Appoints Chris Vasquez CFO, Succeeding Richard Waldron
SEC.
Benzinga · Mar 2, 2026
BioAtla Board Initiates Formal Process To Explore And Evaluate Strategic Options To Monetize Assets
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the
Benzinga · Jan 27, 2026
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
